1. Home
  2. AURE vs SCYX Comparison

AURE vs SCYX Comparison

Compare AURE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AURE

Prestige Wealth Inc. Class A Ordinary Shares

N/A

Current Price

$2.50

Market Cap

64.0M

Sector

Finance

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.66

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AURE
SCYX
Founded
2018
1999
Country
Hong Kong
United States
Employees
4
29
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.0M
60.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
AURE
SCYX
Price
$2.50
$0.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
51.1K
344.2K
Earning Date
06-01-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.57
52 Week High
$3.53
$1.29

Technical Indicators

Market Signals
Indicator
AURE
SCYX
Relative Strength Index (RSI) 57.39 30.24
Support Level $2.33 $0.67
Resistance Level $2.70 $0.70
Average True Range (ATR) 0.12 0.06
MACD 0.01 -0.03
Stochastic Oscillator 67.44 12.44

Price Performance

Historical Comparison
AURE
SCYX

About AURE Prestige Wealth Inc. Class A Ordinary Shares

Aurelion Inc is a Tether Gold (XAUT) Real World Asset (RWA) company focused on developing a business around tokenized gold. XAUT combines the stability of physical gold with the efficiency of blockchain, providing investors access to a tokenized gold reserve that could serve as a haven to inflation, currency devaluation, and crypto volatility. In parallel to building a business around the development of tokenized gold, Aurelion provides wealth management and asset management services.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: